Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Relying on kaoxipian (Ankangxin)

This product is suitable for -Treatment of symptoms and signs of acute and chronic osteoarthritis -Treatment of acute gouty arthritis -Treatment of primary dysmenorrhea Prescription of selective cyclooxygenase-2 inhibitors should be based on a comprehensive assessment of the risk of individual patients (see [precautions]). More role
App download minus 10 yuan
Common name:
Etocoxib tablets
Product No.:
C14202049751
Approval No.:
Gyzz j20180057 (former gyzz j20130130133) (inquired by the State Drug Administration)
Jianke price:
¥50.25
Product specification:
60mg*5s 120mg*5s 120mg * 5 tablets + 40mg * 14 tablets 60mg * 5S * 5 boxes + 100 pieces
Manufacturer:
Frosst Iberica SA
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Relying on kaoxipian (Ankangxin)
Main raw materials The main ingredient is Kaoxi.
Main role This product is suitable for -Treatment of symptoms and signs of acute and chronic osteoarthritis -Treatment of acute gouty arthritis -Treatment of primary dysmenorrhea Prescription of selective cyclooxygenase-2 inhibitors should be based on a comprehensive assessment of the risk of individual patients (see [precautions]).
Product specification 60mg*5s
Usage and dosage This product is used for oral administration. It can be taken with food or alone. arthritis The recommended dose is 30mg once a day. For patients whose symptoms can not be fully relieved, it can be increased to 60mg once a day. After using 60mg once a day, the curative effect is still not obvious after 4 weeks. Other treatment methods should be considered. Acute gouty arthritis The recommended dose is 120mg, which can be increased to 60mg once a day for patients who can not fully alleviate. When the curative effect is not obvious after 4 weeks, other treatment methods should be considered. Acute gouty arthritis The recommended dose is 120mg once a day,. 120mg of this product is only applicable to the acute onset of symptoms, with a maximum use of 8 days. When the dosage is greater than the recommended dose, it has not been proved to have better efficacy or has not been studied at present. Therefore, the maximum dose for the treatment of bone and joint is no more than 60mg per day The maximum recommended dose for the treatment of acute gouty arthritis is no more than 120mg per day. [see the instructions for details]
manufacturing enterprise Frosst Iberica SA
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Relying on kaoxipian (Ankangxin)

[common name] Etocoxib tablets

[specification and model] 60mg*5s

[manufacturer] Frosst Iberica SA

[drug type] Western medicine

[approval No.] Gyzz j20180057 (former gyzz j20130130133)

[validity period] 36 months

[functional indications] This product is suitable for -Treatment of symptoms and signs of acute and chronic osteoarthritis -Treatment of acute gouty arthritis -Treatment of primary dysmenorrhea Prescription of selective cyclooxygenase-2 inhibitors should be based on a comprehensive assessment of the risk of individual patients (see [precautions]).

[usage and dosage] This product is used for oral administration. It can be taken with food or alone. arthritis The recommended dose is 30mg once a day. For patients whose symptoms can not be fully relieved, it can be increased to 60mg once a day. After using 60mg once a day, the curative effect is still not obvious after 4 weeks. Other treatment methods should be considered. Acute gouty arthritis The recommended dose is 120mg, which can be increased to 60mg once a day for patients who can not fully alleviate. When the curative effect is not obvious after 4 weeks, other treatment methods should be considered. Acute gouty arthritis The recommended dose is 120mg once a day,. 120mg of this product is only applicable to the acute onset of symptoms, with a maximum use of 8 days. When the dosage is greater than the recommended dose, it has not been proved to have better efficacy or has not been studied at present. Therefore, the maximum dose for the treatment of bone and joint is no more than 60mg per day The maximum recommended dose for the treatment of acute gouty arthritis is no more than 120mg per day. [see the instructions for details]

[adverse reactions] According to foreign literature reports In the clinical trial, about 4800 individuals were evaluated for safety, including about 3400 patients with osteoarthritis, rheumatoid arthritis or chronic low back pain (about 600 patients with osteoarthritis or rheumatoid arthritis were treated for 1 year or more). The following drug-related adverse events were reported in several clinical studies conducted for 12 weeks in patients with osteoarthritis, rheumatoid arthritis or chronic low back pain. The incidence in patients treated with Ankangxin was ≥ 1% and higher than that in placebo group: weakness / fatigue, dizziness, lower limb edema, hypertension, dyspepsia, heartburn, nausea, headache and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased. The incidence of adverse events was similar in patients with osteoarthritis or rheumatoid arthritis treated with Ankangxin for 1 year or more. In another clinical study of 7111 patients with osteoarthritis, etocoxib 90 mg (equivalent to 1.5 times the dose for the treatment of osteoarthritis) was compared Gastrointestinal tolerance of once daily and 50 mg diclofenac sodium three times daily for 9 months. The incidence of adverse events of Ankangxin is roughly similar to that reported in phase IIB or III placebo-controlled clinical studies; however, the incidence of adverse events of hypertension in Ankangxin group is higher than that in diclofenac group. In a clinical study of ankylosing spondylitis, patients received Ankangxin 90 mg once a day for 1 year (126 patients). The incidence of adverse events in this study was similar to the results of long-term studies of osteoarthritis, rheumatoid arthritis and chronic low back pain. In a clinical study of acute gouty arthritis, patients were treated with Ankangxin 120 mg once a day for 8 days. The incidence of adverse events in this study was similar to those reported in osteoarthritis, rheumatoid arthritis and chronic low back pain. In the clinical study of acute analgesia, patients were treated with Ankangxin 120 mg once a day for 1 to 7 days. The incidence of adverse events in these studies was roughly similar to the comprehensive report of the study of osteoarthritis, rheumatoid arthritis and chronic low back pain. Post marketing medication experience: The following adverse reactions were reported after Ankangxin was listed: Abnormal immune system: allergic reaction, including allergic or allergic like reaction; Mental disorders: anxiety and insomnia; Nervous system abnormalities: taste disorders, drowsiness; Cardiac abnormalities: congestive heart failure; Vascular abnormalities: hypertensive crisis; Respiratory, chest and mediastinal abnormalities: bronchospasm; Gastrointestinal abnormalities: abdominal pain, oral ulcer, peptic ulcer, including perforation and bleeding (mainly in elderly patients), vomiting and diarrhea. Hepatobiliary abnormalities: hepatitis. Skin and subcutaneous tissue abnormalities: angioedema, pruritus, rash, Stevens Johnson syndrome, rubella. Abnormalities of kidney and urinary system: renal insufficiency, including renal failure, can generally be recovered after drug withdrawal (see Precautions). See the inner packaging instructions for details.

[precautions] Clinical trials suggest that selective cyclooxygenase-2 inhibitors have thrombotic events (especially myocardial infarction and stroke) compared with placebo and some non steroidal anti-inflammatory drugs (naproxen) Because the cardiovascular risk of selective cyclooxygenase-2 inhibitors may increase with the increase of dose and medication time, the medication time should be shortened as much as possible and the daily minimum effective dose should be used. The remission of patients' symptoms and patients' response to treatment should be evaluated regularly. Patients with significant cardiovascular risk factors (such as hypertension, hyperlipidemia, diabetes mellitus, smoking) or peripheral arterial disease must consider carefully before using Ankang therapy. Selective cyclooxygenase-2 inhibitor can not replace aspirin for cardiovascular prevention because it does not inhibit platelet aggregation. Ankangxin is one of these drugs, which can not inhibit platelet aggregation, so antiplatelet therapy can not be stopped. Gastrointestinal adverse events (gastrointestinal ulcers or other gastrointestinal complications) occur when etocoxib, other selective cyclooxygenase-2 inhibitors, and NSAIDs are combined with aspirin (even at the lowest dose) The difference in gastrointestinal safety between the combination of selective cyclooxygenase-2 inhibitors and aspirin and the combination of NSAIDs and aspirin has not been evaluated in long-term clinical studies. Ankangxin is not recommended for the treatment of patients with advanced renal diseases. The clinical experience of Ankangxin in patients with creatinine clearance rate < 30ml / min is very limited. If Ankangxin must be used to start the treatment of these patients, it is recommended to closely monitor the patient's renal function. Prostaglandins secreted by the kidney may play a compensatory role in maintaining renal perfusion. Therefore, when renal perfusion is damaged, the use of Ankangxin can reduce prostaglandin production, and then reduce renal blood flow, thus damaging renal function. Patients sensitive to this response include patients with obvious renal insufficiency, decompensated heart failure or liver cirrhosis. These patients should be considered Like other known drugs that can inhibit prostaglandin synthesis, Ankangxin is expected to return to its pre-treatment state after stopping Ankangxin. For patients with obvious dehydration, Ankangxin should be used with caution. It is recommended to rehydrate before starting Ankangxin treatment. Like other drugs known to inhibit prostaglandin synthesis, some patients can observe fluid retention, edema and hypertension after Taking Ankang. * * patients with oedema, hypertension or heart failure should take into account the possibility of fluid retention, edema or hypertension. Ankang is compared with some NSAIDs and other selective cyclooxygenase -2 inhibitors. Especially at high doses, hypertension may occur more frequently or more severe hypertension. Therefore, when using Ankangxin treatment, pay close attention to blood pressure monitoring. If the blood pressure increases significantly, other treatment must be considered. Doctors should note that some patients may develop upper gastrointestinal (GL) unrelated to treatment Ulcer / ulcer complications. In the clinical study, the risk of upper gastrointestinal ulcer detected by endoscopy in patients taking Ankangxin 120 mg once daily was lower than that in patients using non selective NSAIDs, but higher than that in the placebo group. There were upper gastrointestinal ulcer / ulcer complications in patients treated with Ankangxin. There were gastrointestinal perforation, ulcer and bleeding in the past Patients with blood (PUB) history and patients over 65 years old have a higher risk of pub, which has nothing to do with taking Ankangxin treatment. In the clinical study of taking 60 mg and 90 mg of Ankangxin daily for 1 year, it was found that about 1% of patients had increased alanine aminotransferase and / or aspartate aminotransferase (about 3 times or more of the upper limit of normal) In the drug clinical control study, the incidence of increased aspartate aminotransferase and / or alanine aminotransferase in the patients treated with 60 and 90 mg of Ankangxin per day was similar to that in the patients treated with naproxen, but significantly lower than that in the diclofenac group. In the patients treated with Ankangxin, the increase of aspartate aminotransferase and / or alanine aminotransferase could be recovered, of which about The aspartate aminotransferase and / or alanine aminotransferase in semi mature patients returned to normal during continued treatment. For patients whose symptoms and / or signs suggest abnormal liver function, or whose liver function is verified by chemistry, whether there is persistent abnormal liver function should be evaluated. If the liver function is persistent abnormal (3 times the upper limit of normal), Ankangxin treatment should be stopped. For patients with acute asthma, urticaria or rhinitis caused by salicylate or non selective cyclooxygenase inhibitors in the past, Ankangxin should be used with caution. Because the pathophysiological mechanism of these reactions is not clear, doctors should weigh the benefits and potential risks of Ankangxin. In addition, Ankangxin can cover up the sign of infection - fever. Pay attention when applying Ankangxin to patients undergoing anti infection treatment. Please read the instructions carefully and follow the doctor's instructions.

[taboo] Ankangxin is prohibited for the following patients. Allergic to any of its ingredients; Congestive heart failure (New York Heart Association [NYHA] cardiac function classification II - IV); Diagnosed ischemic heart disease and / or cerebrovascular disease (including patients who have recently undergone coronary artery bypass grafting or angioplasty).

[listing Permit Holder] Merck&Co,Inc.U.S.A

[packaging unit] box

[main ingredients] The main ingredient is Kaoxi.

[character] This product is dark green, film coated piece, with arcoxia60 engraved on one side and 200 engraved on the other side.

[applicable population] unlimited

[medication for pregnant and lactating women] Ankangxin, like other drugs known to inhibit prostaglandin synthesis, can cause early closure of arterial catheter. The application of Ankangxin in late pregnancy should be avoided. Reproductive studies in rats showed that no developmental abnormalities were found when the dose of Ankangxin was as high as 15mg / kg / day [equivalent to 1.5 times the human dose (90mg)). In the experimental study on the treatment of rabbits with etocoxib, a very low incidence of cardiovascular malformations and an increase in the incidence of post implantation failure were found when the dose was about twice the human dose (90 mg), while no developmental abnormalities were found when the dose was about equal to or lower than the daily human dose (90 mg). But animal reproductive research does not always predict human responses. At present, there is no appropriate and strictly controlled study on pregnant women. Therefore, in the first 6 months of pregnancy, Ankangxin can be used only when the possible benefits outweigh the potential risks to the fetus. Ankangxin can be secreted with the milk of lactating rats. It is not clear whether Ankangxin is secreted by human milk. Because many drugs can be secreted through human milk, and drugs that inhibit prostaglandin synthesis may have adverse effects on lactating infants, the effect of drugs on mothers should be considered to decide whether to terminate lactation or stop drugs.

[medication for children] Ankangxin has not yet established its safety and efficacy in children.

[medication for elderly patients] The pharmacokinetic characteristics of the elderly (65 years and older) are similar to those of the young. Clinical studies have also confirmed that Ankangxin has no difference in safety and efficacy between elderly patients and young patients.

[storage] Store under 30 ℃ in the original package.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Relying on kaoxipian (Ankangxin)

    ¥50.25

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!